MESO Q4 2022 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+11.4% YoY

Gross Profit

-$14M-623.0% margin

Operating Income

-$20M-890.6% margin

Net Income

-$21M-964.7% margin

EPS (Diluted)

$-0.33

QoQ Revenue Growth

+10.6%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$662M

Total Liabilities

$165M

Stockholders' Equity

$497M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	+11.4%
Gross Profit	-$14M	-$12M	-14.8%
Operating Income	-$20M	-$19M	-2.7%
Net Income	-$21M	-$22M	+2.7%